FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC :

Osimertinib was previously approved as a monotherapy, the first-in-line global standard of care, for non–small cell lung cancer indications.

Related Keywords

, Davida Litman , Dave Fredrickson , Astrazeneca , Dana Farber Cancer Institute , Osimertinib With , Line Treatment , Completion Date , Oncology Business Unit , Thenew England Journal , Yang Jc H , Mutated Advanced ,